secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuo Therapeutics, Inc. (AURX)
CIK:        0001091596
Form:       8-K
Filed at:   2026-05-14T21:11:29+00:00
Accession:  0001437749-26-017116
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows
-------------------------------------------------------------------------

- Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.
- Aurix branded product revenue rose over 30% sequentially versus Q4 2025.
- Net operating loss improved to $446,000 from $745,000 in Q1 2025.
- Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.
- CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/0001437749-26-017116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/aurx20260514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer